Sotyktu® is the commercial brand name of Deucravacitinib Tablets, an orally active selective tyrosine kinase 2 (TYK2) inhibitor developed by Bristol Myers Squibb. It selectively binds to the TYK2 JH2 domain to inhibit TYK2-mediated signaling, regulates multiple pro-inflammatory cytokine pathways, and suppresses excessive autoimmune inflammatory responses.
Main Indications
Treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Clinical Research
Global multicenter phase III POETYK PSO-1 and POETYK PSO-2 pivotal trials confirmed significant skin lesion clearance and durable clinical response in patients with moderate-to-severe plaque psoriasis receiving deucravacitinib monotherapy;
Long-term open-label extension cohorts demonstrated sustained efficacy and consistent safety profile during continuous oral administration;
Dose-finding research verified balanced anti-inflammatory efficacy and systemic tolerability of the 6 mg once-daily standard dose;
Chinese domestic registration trials confirmed consistent therapeutic activity and manageable adverse reaction spectrum for domestic plaque psoriasis populations
Common Side Effects
Common mild adverse reactions: Upper respiratory tract infection, nausea, headache, acne and elevated blood creatine kinase;
Laboratory abnormalities: Transient mild increase in liver transaminases;
Severe but uncommon risks: Serious infection, hypersensitivity reactions and rhabdomyolysis.
Approval Status in China
Original drug Sotyktu® (Deucravacitinib Tablets) was officially approved for marketing in China in 2023, with the specification of 6 mg per tablet, 7 tablets per box. It is currently a prescription targeted anti-inflammatory drug included in China’s Category B medical insurance catalogue.
Buy Sotyktu (Deucravacitinib Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
